Literature DB >> 8256920

T-lymphocytes with gamma delta+ V delta 2+ antigen receptors are present in increased proportions in a fraction of patients with tuberculosis or with sarcoidosis.

B Balbi1, M T Valle, S Oddera, D Giunti, F Manca, G A Rossi, L Allegra.   

Abstract

T-lymphocytes with T-cell antigen receptor (TCR) comprising a gamma chain and a delta chain (gamma delta+ T cells) are believed to be involved in the immune reaction to mycobacterial antigens, and they have been found in increased proportions in sarcoid patients. We evaluated the proportions of gamma delta+ T-lymphocytes and of two major gamma delta+ subpopulations, the V delta 1+ and the V delta 2+ T-cell subsets, in 10 normal blood donors, in 15 patients with tuberculosis (TB), seven of whom had pleural effusion (PE), and in 12 patients with pulmonary sarcoidosis (PS), nine of whom underwent bronchoalveolar lavage (BAL). T-cell subsets were evaluated in peripheral blood (PBL) of all subjects and in PE from patients with TB and in BAL from patients with PS. Compared with normal blood donors, patients with TB had increased proportions of PBL CD3+ gamma delta+ T cells (6 +/- 1% versus 14 +/- 3% of CD3+ T cells, p < 0.05) because of the presence of four patients who had an increase (respectively, 18.3, 22.0, 24.2, and 35.4% of CD3+ T cells) of gamma delta+ T cells. In patients with TB and PE, gamma delta+ T cells were 7.9 +/- 2.7%, a value not different from that in the tubercular PBL and in normal PBL. Although patients with PS had proportions of PBL gamma delta+ T cells (9.2 +/- 3.4%) similar to those in normal PBL, two patients had increased (35 and 31%) PBL gamma delta+ T-lymphocytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256920     DOI: 10.1164/ajrccm/148.6_Pt_1.1685

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  41 in total

Review 1.  Tissue distribution, antigen specificity and effector functions of gamma delta T cells in human diseases.

Authors:  G De Libero
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system.

Authors:  C T Morita; R A Mariuzza; M B Brenner
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Vgamma2Vdelta2+ T cells and anti-microbial immune responses.

Authors:  Zheng W Chen; Norman L Letvin
Journal:  Microbes Infect       Date:  2003-05       Impact factor: 2.700

Review 4.  Adaptive immune response of Vgamma2Vdelta2 T cells: a new paradigm.

Authors:  Zheng W Chen; Norman L Letvin
Journal:  Trends Immunol       Date:  2003-04       Impact factor: 16.687

5.  Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

Authors:  H Veenstra; R Baumann; N M Carroll; P T Lukey; M Kidd; N Beyers; C T Bolliger; P D van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 6.  gamma/delta and other unconventional T lymphocytes: what do they see and what do they do?

Authors:  S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 7.  Recognition of nonpeptide antigens by T cells.

Authors:  Y Tanaka; M B Brenner; B R Bloom; C T Morita
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

Review 8.  Mycobacteria and sarcoidosis.

Authors:  O M Kon; R M du Bois
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

9.  Gammadelta+ and CD4+ alphabeta+ human T cell subset responses upon stimulation with various Mycobacterium tuberculosis soluble extracts.

Authors:  G Batoni; S Esin; R A Harris; G Källenius; S B Svenson; R Andersson; M Campa; H Wigzell
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

10.  TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells.

Authors:  Haishan Li; Kun Luo; C David Pauza
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.